M&A Deal Summary

Esteve Pharmaceuticals S.A. Acquires Riemser Arzneimittel AG

On January 8, 2020, Esteve Pharmaceuticals S.A. acquired life science company Riemser Arzneimittel AG from Ardian

Acquisition Highlights
  • This is Esteve Pharmaceuticals S.A.’s 1st transaction in the Life Science sector.
  • This is Esteve Pharmaceuticals S.A.’s 1st transaction in Germany.

M&A Deal Summary
Date 2020-01-08
Target Riemser Arzneimittel AG
Sector Life Science
Buyer(s) Esteve Pharmaceuticals S.A.
Sellers(s) Ardian
Deal Type Add-on Acquisition

Target

Riemser Arzneimittel AG

Greifswald - Insel Riems, Germany
Riemser Arzneimittel AG is a pharmaceutical company focuses on its activities is mainly due to the distribution and life cycle management of pharmaceuticals in therapeutic niche areas with high unmet medical needs. Riemser product range especially covers prescription drugs to treat serious diseases in the therapeutic areas of oncology, infectiology, neurology, in the cardiovascular field, in dermatology, rheumatology, tuberculosis treatment, for the treatment of obesity and primary axillary hyperhidrosis.

Search 202,137 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Esteve Pharmaceuticals S.A.

Barcelona, Spain
Category Company
Founded 1929
Sector Life Science
Employees2,300
Revenue 758M EUR (2018)
DESCRIPTION

Esteve Pharmaceuticals, S.A. is a global pharmaceutical company offers solutions in the pharmaceutical segment, mainly in Spain with a broad and highly innovative product portfolio and as a global Contract Manufacturing Organization (CMO). ESTEVE is at present advancing in its transformation journey to become an international proprietary specialty pharmaceutical company.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (Germany) 1 of 1
Year (2020) 1 of 1

Seller(S) 1

SELLER

Ardian

Paris, France

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 1996
PE ASSETS 125.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

Ardian is a mega-sized diversified investment group focused on opportunities worldwide. Ardian invests across and manages funds focused on small and mid-sized buyouts, growth capital financings, mezzanine, infrastructure, real estate, and co-investment opportunities. Ardian's small-buyouts group targets controlling interests in French, German, and Italian businesses valued up to €100 million. It's mid-sized buyout group seeks businesses valued up €1.5 billion and does not have any geographic limitations. The Infrastructure team looks for European opportunities and can commit up to €150 million per transaction. The Mezzanine group supports junior capital commitments of €5 to €80 million. In addition to direct investing, Ardian also manages various private equity fund-of-funds. Ardian was founded in 1996 and is based in Paris.

DEAL STATS #
Overall 175 of 224
Sector (Life Science) 5 of 8
Type (Add-on Acquisition) 45 of 53
Country (Germany) 15 of 20
Year (2020) 2 of 16
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-01-01 Custom Solutions

France

Custom Solutions specialized in sales promotion and e-logistics. The company's historical core business line is the management of promotional marketing for mass-market brands: payback, deferred bonuses and shops, quizzes and multimedia games. Custom Solutions also provides outsourcing services for POS-A (point of sale advertising) logistics and e-logistics.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-01-16 Frulact

Gemunde - Maia, Portugal

Frulact is a producer of natural fruit-based and plant-based specialty ingredients for the Food & Beverage industry. The Group has a global presence across three continents, with nine business units in five countries (Portugal, Morocco, France, South Africa, and Canada). Frulact was founded in 1987 and is based in Gemunde - Maia, Portugal.

Buy -
Mergr

Product

Company

Legal